These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 8748629

  • 1. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES, Factor SA, Weiner WJ, Sanchez-Ramos JR, Singer C, Shulman L, Brown D, Sheldon C.
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [Abstract] [Full Text] [Related]

  • 2. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG.
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 5. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
    Künig G, Pogarell O, Möller JC, Delf M, Oertel WH.
    Clin Neuropharmacol; 1999 Apr; 22(5):301-5. PubMed ID: 10516884
    [Abstract] [Full Text] [Related]

  • 6. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
    Möller JC, Oertel WH, Köster J, Pezzoli G, Provinciali L.
    Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
    [Abstract] [Full Text] [Related]

  • 7. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 8. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort InvestigatorsDepartment of Neurology, University of Rochester, 1351 Mt Hope Ave, Ste 220, Rochester, NY 14620, USA. kevin.biglan@ctcc.rochester.edu.
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [Abstract] [Full Text] [Related]

  • 9. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
    Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Meco G.
    Funct Neurol; 2002 May; 17(4):199-201. PubMed ID: 12675263
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
    JAMA; 1997 Jul 09; 278(2):125-30. PubMed ID: 9214527
    [Abstract] [Full Text] [Related]

  • 13. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W.
    Mov Disord; 2010 Nov 15; 25(15):2542-9. PubMed ID: 20669317
    [Abstract] [Full Text] [Related]

  • 14. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group.
    Arch Neurol; 2005 Feb 15; 62(2):241-8. PubMed ID: 15710852
    [Abstract] [Full Text] [Related]

  • 15. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A, Althoff R, Martineau RJ, Jacobson J.
    Am J Psychiatry; 2005 Apr 15; 162(4):814-5. PubMed ID: 15800169
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
    Pinter MM, Pogarell O, Oertel WH.
    J Neurol Neurosurg Psychiatry; 1999 Apr 15; 66(4):436-41. PubMed ID: 10201413
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.
    Holman AJ, Myers RR.
    Arthritis Rheum; 2005 Aug 15; 52(8):2495-505. PubMed ID: 16052595
    [Abstract] [Full Text] [Related]

  • 20. An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson's disease.
    Pinter MM, Rutgers AW, Hebenstreit E.
    J Neural Transm (Vienna); 2000 Aug 15; 107(11):1307-23. PubMed ID: 11145006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.